Ask about this productRelated genes to: LRCH4 antibody
- Gene:
- LRCH4 NIH gene
- Name:
- leucine rich repeats and calponin homology domain containing 4
- Previous symbol:
- LRN, LRRN1
- Synonyms:
- -
- Chromosome:
- 7q22.1
- Locus Type:
- gene with protein product
- Date approved:
- 1998-06-03
- Date modifiied:
- 2019-02-11
Related products to: LRCH4 antibody
Related articles to: LRCH4 antibody
- Modern advancements in precision medicine have led to the generation of vast proteomic datasets, capturing the concentrations of thousands of proteins across tens of thousands of participants. These datasets are traditionally processed using supervised learning methods due to their relative simplicity to implement and assess the output. However, this approach can sometimes overlook subtle patterns that might offer deeper insights. In contrast, unsupervised learning, while capable of revealing hidden relationships, struggles with the challenge of high dimensionality, meaning that brute-force analysis could take millennia to complete. In this study, we developed the Dimensionality Reduction with Avoidance of Missing/COmmunity Detection (DIRAM/COD) framework to address this problem by combining dimensionality reduction techniques with unsupervised learning to analyze the massive proteomic dataset of the UK Biobank, which includes the concentrations of 2,923 plasma proteins from 52,691 participants. By applying this novel approach, we not only confirmed well-established biomarkers for diseases such as hypertension (UBE2L6) and leukemia (LRCH4) but also identified novel protein candidates. For instance, we identified IGF2BP3 in connection with celiac disease, a protein previously linked to intestinal barrier function, along with several other proteins not yet associated with these diseases. This approach opens up exciting possibilities for future research and may pave the way for the discovery of new biomarkers and therapeutic targets. - Source: PubMed
Publication date: 2026/02/22
Bernard ElvisWang YilingChen ManlinXu Shunqing - Lymphocytic variant hypereosinophilic syndrome (L-HES) is a rare subtype of hypereosinophilic syndrome driven by aberrant T-cell clones that promote eosinophilia through interleukin-5 (IL-5) overproduction. While clonal T-cell receptor (TCR) rearrangements are a hallmark, the underlying genetic landscape remains poorly defined. - Source: PubMed
Publication date: 2025/12/18
Walkenhorst MollyBasu Malay KCui WeiKumar ManishVallurupalli AnushaSitek AndreaZhao XinyangZheng X LongZhang Da - High-throughput, label-free quantitative proteomic analyses, along with cell viability and reactive oxygen species (ROS) studies, were performed on MDA-MB-468 human triple-negative breast cancer (TNBC) cells, to gain mechanistic insights into therapeutic actions. TNBC was chosen as it is the most lethal subtype of breast cancer, highly aggressive, prone to recurrence and metastasis, with the highest prevalence in black women. The absence of specific biomarkers limits targeted therapies. This unmet need was studied using proteomics, after treating the cells with electrical pulses (EP) combined with metformin (met). With the EP + met treatment (1000 V/cm, 1 mM), cell viability dropped to 25.6 % after 24 h and ROS increased to 179 %, compared to control at 100 %. Proteomics revealed 125 upregulated and 37 downregulated proteins in EP + met, compared to met alone, involving enzymes, proliferation markers, and kinases. Key gene changes included upregulation of ALAD, MKI67, and LRCH4, and downregulation of EIF1AX, NSUN5, and GNS. LRCH4 and GNS are suggested to be potential novel therapeutic targets, as LRCH4 upregulation links to inhibition of the mTOR/PI3K/Akt pathway, reducing proliferation, while GNS downregulation suppresses tumor growth and metastasis. Overall, proteomics-based preliminary findings suggest that EP + met modulate TNBC pathways, identifying potential biomarkers and providing a foundation for future validation. - Source: PubMed
Publication date: 2025/10/24
Sahu PraveenCamarillo Ignacio GSundararajan Raji - Familial adenomatous polyposis (FAP) is regarded as a precancerous stage of colon adenocarcinoma (COAD). COAD concurrent with FAP is quite rare in colorectal cancer screening. In order to create a new COAD prognostic prediction model and to shed light on the landscape of the tumor immune microenvironment in COAD, we examined differentially expressed genes (DEGs) between COAD and FAP in this study. - Source: PubMed
Publication date: 2025/06/25
Li Shi-QinJiang WeiZhu Yu-Cheng - Colorectal cancer is one of the most common gastrointestinal malignancies worldwide. LRCH4 is the top 1 gene associated with an unfavorable prognosis in colorectal cancer. - Source: PubMed
Li ZhiwenCui ZhenhuaWang XianrenLv Yanfeng